Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.

Gu M, Hine PM, James Jackson W, Giri L, Nabors GS.

Vaccine. 2007 Jan 5;25(3):526-34. Epub 2006 Aug 17.

PMID:
16973247
2.

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS, Nielsen CJ.

Vaccine. 2011 Aug 26;29(37):6313-20. doi: 10.1016/j.vaccine.2011.05.047. Epub 2011 May 30.

PMID:
21624418
3.

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP.

Vaccine. 2007 Apr 12;25(15):2771-7. Epub 2007 Jan 2.

PMID:
17240008
4.

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.

Klinman DM, Xie H, Little SF, Currie D, Ivins BE.

Vaccine. 2004 Jul 29;22(21-22):2881-6.

PMID:
15246624
5.

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP.

Vaccine. 2004 Jan 2;22(3-4):422-30.

PMID:
14670324
6.

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Berthold I, Pombo ML, Wagner L, Arciniega JL.

Vaccine. 2005 Mar 14;23(16):1993-9.

PMID:
15734073
7.

An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.

Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ.

Vaccine. 2008 Aug 5;26(33):4262-6. doi: 10.1016/j.vaccine.2008.05.068. Epub 2008 Jun 12.

PMID:
18586363
8.

CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.

Klinman DM, Xie H, Ivins BE.

Ann N Y Acad Sci. 2006 Oct;1082:137-50. Review.

PMID:
17145935
9.

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL.

Vaccine. 2009 Jul 16;27(33):4537-42. doi: 10.1016/j.vaccine.2009.05.045. Epub 2009 Jun 6.

PMID:
19501205
10.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
12.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11. Epub 2007 May 18.

PMID:
17881903
13.

Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).

Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW.

Vaccine. 2014 Nov 28;32(50):6847-54. doi: 10.1016/j.vaccine.2014.01.096. Epub 2014 Feb 13.

14.

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.

Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.

Vaccine. 2006 May 1;24(18):3953-63. Epub 2006 Feb 28.

PMID:
16530302
15.

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW.

Vaccine. 2004 Aug 13;22(23-24):3136-43.

PMID:
15297066
16.

Development of an in vitro-based potency assay for anthrax vaccine.

Little SF, Webster WM, Ivins BE, Fellows PF, Norris SL, Andrews GP.

Vaccine. 2004 Jul 29;22(21-22):2843-52.

PMID:
15246620
17.
19.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
20.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

Supplemental Content

Support Center